C-X-C motif chemokine ligand 10 (CXCL10/IP10) has been widely reported to be elevated in the plasma of COVID-19 (58), and targeting the chemokine ligand 2-chemokine receptor 2 axis provides potential for immunotherapy in chronic pain (59). Here, CXCL10 is linked to COVID-19.